A Asberg

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi request reprint Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy
    Monica Hermann
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, and Lipid Clinic, Rikshospitalet, Norway
    Clin Pharmacol Ther 79:532-9. 2006
  2. pmc Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients
    Ida Robertsen
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, P, O, Box 1068, Blindern, Oslo, 0316, Norway
    Transplant Res 2:5. 2013
  3. doi request reprint Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial
    Anders Asberg
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Clin Transplant 27:E151-6. 2013
  4. pmc Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients
    Håvard Loftheim
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Transplant Res 1:9. 2012
  5. doi request reprint Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients
    A Asberg
    Department of Pharmaceutical Biosciences, University of Oslo, Oslo, Norway
    Am J Transplant 10:1881-8. 2010
  6. ncbi request reprint Fluvastatin and fluvastatin extended release: a clinical and safety profile
    Anders Asberg
    Medical Department, National Hospital, Oslo, Norway
    Expert Rev Cardiovasc Ther 2:641-52. 2004
  7. doi request reprint Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients
    Anders Asberg
    University of Oslo, School of Pharmacy, PO Box 1068, Blindern, 0316 Oslo, Norway
    Expert Opin Pharmacother 11:1159-66. 2010
  8. doi request reprint Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study
    Anders Asberg
    School of Pharmacy, University of Oslo, Oslo, Norway
    Ther Drug Monit 32:152-8. 2010
  9. doi request reprint Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation
    Anders Asberg
    Laboratory for Renal Physiology, Medical Department, Rikshospitalet Medical Center, Oslo, Norway
    Clin Transplant 23:511-8. 2009
  10. ncbi request reprint Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients
    Anders Asberg
    Laboratory for Renal Physiology, Medical Department, Rikshospitalet, Oslo, Norway
    Transplantation 82:62-8. 2006

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy
    Monica Hermann
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, and Lipid Clinic, Rikshospitalet, Norway
    Clin Pharmacol Ther 79:532-9. 2006
    ..This is the first study to investigate whether the pharmacokinetics of either atorvastatin or its metabolites, or both, is altered in patients with atorvastatin-related myopathy compared with healthy controls...
  2. pmc Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients
    Ida Robertsen
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, P, O, Box 1068, Blindern, Oslo, 0316, Norway
    Transplant Res 2:5. 2013
    ..The aims of this study were to evaluate the relationships between CsA concentrations at different target sites as potential therapeutic drug monitoring (TDM) tools in heart transplant recipients...
  3. doi request reprint Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial
    Anders Asberg
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Clin Transplant 27:E151-6. 2013
    ..CsA withdrawal was associated with a high rate of acute rejections. Initially, the treatment of acute rejections was successful. However, five of six lost their grafts in the long term...
  4. pmc Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients
    Håvard Loftheim
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Transplant Res 1:9. 2012
    ..abstract:..
  5. doi request reprint Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients
    A Asberg
    Department of Pharmaceutical Biosciences, University of Oslo, Oslo, Norway
    Am J Transplant 10:1881-8. 2010
    ..Both mycophenolate and tacrolimus (rather than cyclosporine) therapy seem to be associated with reduced risk of recurrence...
  6. ncbi request reprint Fluvastatin and fluvastatin extended release: a clinical and safety profile
    Anders Asberg
    Medical Department, National Hospital, Oslo, Norway
    Expert Rev Cardiovasc Ther 2:641-52. 2004
    ..The demonstration of the safe use of fluvastatin in a wide range of patients may be associated with the predominant acid form of the drug in vivo, as well as its predominant metabolism via the cytochrome P450 2C9 pathway...
  7. doi request reprint Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients
    Anders Asberg
    University of Oslo, School of Pharmacy, PO Box 1068, Blindern, 0316 Oslo, Norway
    Expert Opin Pharmacother 11:1159-66. 2010
    ..Valganciclovir is a prodrug of ganciclovir with > 60% bioavailability and has become an alternative to intravenous ganciclovir...
  8. doi request reprint Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study
    Anders Asberg
    School of Pharmacy, University of Oslo, Oslo, Norway
    Ther Drug Monit 32:152-8. 2010
    ..A possible favorable effect on short- and long-term outcome needs to be verified in further, properly powered, clinical trials...
  9. doi request reprint Calcineurin inhibitor effects on glucose metabolism and endothelial function following renal transplantation
    Anders Asberg
    Laboratory for Renal Physiology, Medical Department, Rikshospitalet Medical Center, Oslo, Norway
    Clin Transplant 23:511-8. 2009
    ..Calcineurin inhibitors (CNI) are involved in the development of post-transplant diabetes mellitus (PTDM). Changes in insulin secretion and sensitivity contribute to the development of PTDM and are associated with endothelial function...
  10. ncbi request reprint Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients
    Anders Asberg
    Laboratory for Renal Physiology, Medical Department, Rikshospitalet, Oslo, Norway
    Transplantation 82:62-8. 2006
    ..Calcineurin inhibitor (CNI)-free regimens posttransplantation have been claimed to conserve graft function in addition to reduce the risk factors for cardiovascular and malignant disease in renal transplant recipients...
  11. ncbi request reprint Determination of ganciclovir in different matrices from solid organ transplanted patients treated with a wide range of concomitant drugs
    Anders Asberg
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Blindern, Oslo, Norway
    J Pharm Biomed Anal 43:1039-44. 2007
    ..1 microg/mL. The method was successfully applied on clinical samples from renal transplant recipients treated with VGCV in combination with a variety of usually used concomitant drugs for solid organ transplant recipients...
  12. doi request reprint Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients
    A Asberg
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Am J Transplant 9:1205-13. 2009
    ..Persistent DNAemia at day 21, CMV IgG serostatus and development of resistance may be relevant factors for further individualization of treatment...
  13. ncbi request reprint Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients
    A Asberg
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Am J Transplant 7:2106-13. 2007
    ....
  14. doi request reprint Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch
    I B Skottheim
    School of Pharmacy, University of Oslo, Oslo, Norway
    Clin Pharmacol Ther 87:699-705. 2010
    ..Consequently, retitration to the lowest effective dose should be considered after biliopancreatic diversion with duodenal switch in the case of drugs with a high degree of intestinal first pass metabolism and a narrow therapeutic window...
  15. ncbi request reprint Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients
    A Asberg
    Medical Department, The National Hospital, Oslo, Norway
    Am J Transplant 1:382-6. 2001
    ..0% (p < 0.0001), respectively. Bilateral pharmacokinetic interaction between atorvastatin and CsA resulted in sixfold higher plasma HMG-CoA reductase inhibitory activity, but only a moderate decrease in systemic exposure of CsA...
  16. ncbi request reprint Diltiazem modulates cyclosporin A induced renal hemodynamic effects but not its effect on plasma endothelin-1
    A Asberg
    Department of Pharmacology, School of Pharmacy, University of Oslo, Norway
    Clin Transplant 12:363-70. 1998
    ..These findings suggest that CsA induced acute vasoconstriction and renal hypoperfusion are mediated by ET-1 and that diltiazem treatment abolishes these pharmacodynamic effects of CsA despite persistent increase of plasma ET-1 levels...
  17. ncbi request reprint A simple and sensitive high-performance liquid chromatography assay of diltiazem and main metabolites in renal transplanted patients
    H Christensen
    Department of Pharmacology, School of Pharmacy, University of Oslo, Norway
    Clin Chim Acta 283:63-75. 1999
    ..Plasma samples from renal transplanted patients treated with cyclosporin A and healthy volunteers did not show any interference by cyclosporin A with the determination of diltiazem and metabolites...
  18. ncbi request reprint Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients
    H Holdaas
    Department of Medicine, National Hospital, Sognsvannsveien 20, 0027 Oslo, Norway
    Int J Clin Pharmacol Ther 44:163-71. 2006
    ..To assess the pharmacokinetic interaction between cyclosporine and extended-release fluvastatin (fluvastatin XL), 80 mg for 7 days, in stable renal transplant recipients...
  19. ncbi request reprint Better microvascular function on long-term treatment with lisinopril than with nifedipine in renal transplant recipients
    A Asberg
    Laboratory for Renal Physiology, Section of Nephrology, Medical Department, The National Hospital, Oslo, Norway
    Nephrol Dial Transplant 16:1465-70. 2001
    ..The beneficial microvascular effect may be mediated in part by an endothelin-1-associated effect on the endothelium...
  20. ncbi request reprint Pharmacokinetic interactions between microemulsion formulated cyclosporine A and diltiazem in renal transplant recipients
    A Asberg
    Department of Pharmacology, School of Pharmacy, University of Oslo, Norway
    Eur J Clin Pharmacol 55:383-7. 1999
    ..We performed a pharmacokinetic interaction study in renal transplant recipients, measuring both unmetabolised CsA and diltiazem in addition to three of the main metabolites of diltiazem (MA, M1, M2)...
  21. doi request reprint Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects
    M Ulvestad
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Clin Pharmacol Ther 93:275-82. 2013
    ..149). In conclusion, this study suggests that OATP1B1 phenotype is more important than CYP3A4 and MDR1 phenotypes for the individual pharmacokinetic variability of atorvastatin...
  22. ncbi request reprint Atorvastatin improves endothelial function in renal-transplant recipients
    A Asberg
    Laboratory for Renal Physiology, Section of Nephrology, Medical Department, The National Hospital, N-0027 Oslo, Norway
    Nephrol Dial Transplant 16:1920-4. 2001
    ..Plasma NO levels were increased during atorvastatin treatment, indicating a possible endothelial protective effect through an "endothelial-NO pathway"...
  23. doi request reprint Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients
    I B Skottheim
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Clin Pharmacol Ther 86:311-8. 2009
    ..Because individual first-pass metabolic capacity is not readily assessable clinically, retitration up to the lowest effective dose should be performed after the surgery...
  24. ncbi request reprint Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients
    Anders Asberg
    Laboratory for Renal Physiology, Section of Nephrology, Medical Department, The National Hospital, Oslo, Norway
    Drugs 63:367-78. 2003
    ....
  25. doi request reprint Secreted wnt antagonists during eradication of cytomegalovirus infection in solid organ transplant recipients
    T Ueland
    Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway Faculty of Medicine, University of Oslo, Oslo, Norway
    Am J Transplant 14:210-5. 2014
    ....
  26. ncbi request reprint Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation
    Anders Asberg
    Laboratory for Renal Physiology, Section of Nephrology, Medical Department, The National Hospital, Oslo, Norway
    Clin Transplant 17:385-90. 2003
    ..We therefore performed this study to assess the effect of fluvastatin on endothelial function in renal transplant recipients...
  27. doi request reprint Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout (Oncorhynchus mykiss) hepatocytes
    Kathrin Sabine Ellesat
    Department of Biology, University of Oslo, Oslo, Norway
    Toxicol In Vitro 24:1610-8. 2010
    ..Simvastatin was more toxic than atorvastatin and the lactone form more toxic than the acid form. Exposure time affected atorvastatin and ortho-hydroxy atorvastatin lactone but not simvastatin toxicity...
  28. ncbi request reprint Quantification of mRNA levels of endothelin receptor subtypes and preproEndothelin-1 in renal needle biopsies by competitive reverse transcriptase polymerase chain reaction
    A Asberg
    Institute of Surgical Research, Medical Department B, The National Hospital, University of Oslo, Norway
    Scand J Clin Lab Invest 58:299-306. 1998
    ..The competitive RT-PCR assay described provides an accurate tool for gene expression investigation of the human endothelin system in renal cortical needle biopsies...
  29. ncbi request reprint [Metabolic interactions with statins]
    E Molden
    Avdeling for farmakologi Farmasøytisk institutt Universitetet i Oslo Postboks 1068 Blindern 0316 Oslo
    Tidsskr Nor Laegeforen 121:189-93. 2001
    ..Alteration in metabolic activity is often the underlying mechanism of clinically relevant interactions, thus it is important to make a rational assessment of the risk for metabolic interactions with statins...
  30. ncbi request reprint Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients
    Pål Falck
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, PO Box 1068 Blindern, 0316 Oslo, Norway
    Nephrol Dial Transplant 23:1048-53. 2008
    ..The calcimimetic drug cinacalcet offers a novel therapeutic option to treat post-transplant hypercalcemia and hyperparathyroidism; however, the interaction with calcineurin inhibitors and mycophenolate has not been evaluated...
  31. ncbi request reprint Desacetyl-diltiazem displays severalfold higher affinity to CYP2D6 compared with CYP3A4
    Espen Molden
    Department of Pharmacology, School of Pharmacy, University of Oslo, P O Box 1068 Blindern, N 0316 Oslo, Norway
    Drug Metab Dispos 30:1-3. 2002
    ..Metabolism mediated through CYP2D6 is associated with a substantial interindividual variability, and since M1 expresses pharmacological activity, individual CYP2D6 metabolic capacity might be an aspect to consider when using DTZ...
  32. ncbi request reprint Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers
    Hege Christensen
    Department of Pharmacology, School of Pharmacy, University of Oslo, PO Box 1068 Blindern, 0316 Oslo, Norway
    Eur J Clin Pharmacol 58:515-20. 2002
    ..The objective of the present study was to investigate the effect of grapefruit juice on the pharmacokinetics of diltiazem and the metabolites N-demethyl-diltiazem (MA) and desacetyl-diltiazem (M1)...
  33. doi request reprint Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin
    Rune Amundsen
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Blindern, Oslo, Norway
    Drug Metab Dispos 38:1499-504. 2010
    ..This is also supported by the decreased IC(50) value of CsA after preincubation. This study provides evidence that OATP1B1 inhibition is a relevant mechanism for the interaction observed between CsA and atorvastatin...
  34. ncbi request reprint Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study
    Solbjørg Sagedal
    Department of Internal Medicine, Rikshospitalet University Hospital, Oslo, Norway
    Nephrol Dial Transplant 18:1899-908. 2003
    ..In this prospective, randomized single-centre study pre-emptive therapy with oral ganciclovir is compared with conventional deferred treatment...
  35. ncbi request reprint Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients
    Monica Hermann
    Department of Pharmacology, School of Pharmacy, University of Oslo, PB 1068, Blindern, N 0316 Oslo, Norway
    Eur J Clin Pharmacol 61:59-62. 2005
    ..The aim of the present study was to evaluate the possible influence of atorvastatin on the pharmacokinetics of cyclosporine (INN ciclosporin) and its main metabolites, AM1 and AM9, in renal transplant recipients...
  36. doi request reprint Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients
    Pål Falck
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Transplantation 86:1379-83. 2008
    ..Physiologic functions that may affect pharmacokinetics of drugs are altered in elderly patients. The current study was performed to elucidate the effect of age on cyclosporine A (CsA) pharmacokinetics in renal transplant recipients...
  37. ncbi request reprint New-onset posttransplantation diabetes mellitus: insulin resistance or insulinopenia? Impact of immunosuppressive drugs, cytomegalovirus and hepatitis C virus infection
    Jøran Hjelmesaeth
    Department of Medicine, Rikshospitalet University Hospital, Oslo, Norway
    Curr Diabetes Rev 1:1-10. 2005
    ..Future studies should therefore address the effects of different immunosuppressive regimens on the incidence of PTDM. In addition, the impact of cytomegalovirus infection and hepatitis C on PTDM needs further evaluation...
  38. doi request reprint Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro
    Ine Blankenberg Skottheim
    School of Pharmacy, University of Oslo, Norway
    Eur J Pharm Sci 33:317-25. 2008
    ..These results clearly indicate the need to differentiate between acid and lactone forms in future investigation of statin myotoxicity...
  39. doi request reprint Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients
    Pål Falck
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Transplantation 85:179-84. 2008
    ..We investigated cyclosporine A (CsA) concentrations at the site of action, inside T-lymphocytes, to evaluate its applicability as a new supplementary therapeutic drug monitoring method after renal transplantation...
  40. doi request reprint Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients
    Rune Amundsen
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Transplantation 87:1221-4. 2009
    ..Obesity is a common problem following renal transplantation. Rimonabant, a cannabinoid-1 receptor blocker, offers a new approach for reducing obesity...
  41. ncbi request reprint Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry
    Pål Falck
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Norway
    J Chromatogr B Analyt Technol Biomed Life Sci 852:345-52. 2007
    ..5 to 500 ng/mL for AM1, AM9 and AM19, 1 to 500 ng/mL for AM4N, AM1c and AM1c9 in intracellular matrix, and 2.5 to 3000 ng/mL for all analytes in whole blood. The applicability of the method is shown on patient samples...
  42. ncbi request reprint Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients
    Monica Hagen Voytovich
    Department of Medicine, Section of Nephrology, Laboratory for Renal Physiology, Rikshospitalet University Hospital, 0027 Oslo, Norway
    Nephrol Dial Transplant 20:413-8. 2005
    ..Safety parameters were also addressed...
  43. doi request reprint A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation
    K T Smerud
    Section of Nephrology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
    Am J Transplant 12:3316-25. 2012
    ..Ibandronate was also well tolerated...
  44. ncbi request reprint CYP2D6 is involved in O-demethylation of diltiazem. An in vitro study with transfected human liver cells
    E Molden
    Department of Pharmacology, School of Pharmacy, University of Oslo, Norway
    Eur J Clin Pharmacol 56:575-9. 2000
    ..The aim of this in vitro study was to investigate whether O-demethylation of DTZ is mediated by cytochrome P450-2D6 (CYP2D6)...
  45. ncbi request reprint Intake of grapefruit juice alters the metabolic pattern of cyclosporin A in renal transplant recipients
    M Hermann
    Department of Pharmacology, School of Pharmacy, University of Oslo, Norway
    Int J Clin Pharmacol Ther 40:451-6. 2002
    ..The aim of the present study was to investigate the effect of grapefruit juice on the pharmacokinetics of cyclosporin A (CsA), as Sandimmun Neoral, and its main metabolites, M1, M9 and M4N, in renal transplant recipients...
  46. doi request reprint A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients
    Pål Falck
    Department of Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo, Norway
    Clin Pharmacokinet 48:615-23. 2009
    ..The aim of this model development is to potentially use it in the clinical setting to optimize ciclosporin dosing in renal transplant recipients...
  47. ncbi request reprint Association between insulin resistance and endothelial dysfunction in renal transplant recipients
    Monica Hagen Voytovich
    Department of Medicine, Section of Nephrology, Rikshospitalet University Hospital, Oslo, Norway
    Clin Transplant 20:195-9. 2006
    ..In non-transplanted patients, an association between impaired endothelial function and insulin resistance has been shown. Whether such an association also exists in RTR is unknown...
  48. doi request reprint Didanosine ester prodrugs: synthesis, albumin binding properties and pharmacokinetic studies in rats
    Sverre Høyem
    Department of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, Blindern N 0315 Oslo, Norway
    Eur J Med Chem 44:3874-9. 2009
    ..The data indicate that the prodrug was converted to DDI within minutes after administration. High relative protein binding in vitro holds a promise for validity of the concept using more stable linker bonds...
  49. doi request reprint 2-D hydrophilic interaction liquid chromatography-RP separation in urinary proteomics--minimizing variability through improved downstream workflow compatibility
    Håvard Loftheim
    Department of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo, Oslo, Norway
    J Sep Sci 33:864-72. 2010
    ..The optimized and "streamlined" complex method has shown potential for use in future urinary proteomic studies...
  50. ncbi request reprint The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man
    Jøran Hjelmesaeth
    Morbid Obesity Center, the Hospital in Vestfold HF, Boks 2168, 3103 Tønsberg, Norway
    Nephrol Dial Transplant 22:1743-9. 2007
    ..The objectives of the present study were to investigate the possible adverse effects of ciclosporin A (CsA, Sandimmun Neoral) on insulin secretion and insulin sensitivity (IS) in man...